PDX Model Cohort
Gastric Cancer PDX Models
Advance your gastric cancer drug development using a bank of rare and meticulously curated gastric cancer PDX models directly established from primary and metastatic patient tumors.
Summary
Champions Oncology has developed an advanced cohort of Gastric Cancer PDX Models, offering a comprehensive approach to gastric cancer translational research. Our tumor bank includes 28* patient-derived xenograft models, established directly from patient tumors and biopsies, preserving the original molecular and clinical characteristics while minimizing genetic drift commonly seen in passaged models.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading gastric cancer PDX models cohort showcases low-passage models, each reflecting key clinical characteristics, mutations, and pretreatment history.
Access to a robust bank of gastric cancer PDX models with clinically relevant molecularand pathological characteristics.
Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics, and Phosphoproteomics.
Access to a bank with majority of gastric cancer models pretreated with standard of care therapies, such as oxaliplatin and 5fluorouracil/cisplatin/docetaxel combination therapy.